PTC Therapeutics

-$0.17 (-0.52%) Today

$0.00 (0.00%) As of 8:00 PM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTCT and other ETFs, options, and stocks.

About PTCT

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.

CEO

Stuart Walter Peltz

Employees

1,177

Headquarters

South Plainfield, New Jersey

Founded

1998

PTCT Key Statistics

Market cap

Price-Earnings ratio

—

Dividend yield

—

Average volume

651.12K

High today

$33.47

Low today

$31.44

Open price

$32.87

Volume

727.30K

52 Week high

$45.80

52 Week low

$30.03

PTCT News

Benzinga8h

Europe's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic Disorder

by The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of PTC Therapeutics Inc's PTCT Upsta

Analyst ratings

Buy

45.5%

Hold

45.5%

Sell

9.1%

PTCT Earnings

-$2.03

-$1.35

-$0.68

$0.00

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Estimated

— per share

Actual

Expected Jul 28, After Hours

Why Robinhood?

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. View more

Europe's CHMP Backs Approval Of PTC Therapeutics' Gene Therapy In Rare Neurometabolic Disorder

45%

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.